Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma
F50067（一种人源化抗CXCR4单克隆抗体）单药治疗以及与来那度胺和低剂量地塞米松联合治疗复发或难治性多发性骨髓瘤的I期剂量递增研究
期刊:Oncotarget
影响因子:
doi:10.18632/oncotarget.25156
Fouquet, Guillemette; Guidez, Stéphanie; Richez, Valentine; Stoppa, Anne-Marie; Le Tourneau, Christophe; Macro, Margaret; Gruchet, Cécile; Bobin, Arthur; Moya, Niels; Syshenko, Thomas; Sabirou, Florence; Levy, Anthony; Franques, Paul; Gardeney, Hélène; Karlin, Lionel; Benboubker, Lotfi; Ouali, Monia; Vedovato, Jean-Claude; Ferre, Pierre; Pavlyuk, Mariya; Attal, Michel; Facon, Thierry; Leleu, Xavier
